Bausch + Lomb brings new eye redness treatment to retail
Bausch + Lomb on Monday launched Lumify (brimonidine tartrate ophthalmic solution 0.025%), an over-the-counter eye drop developed with low-dose brimonidine tartrate for the treatment of eye redness.
"With the availability of Lumify, consumers now have an innovative, over-the-counter treatment option that can help relieve red, irritated eyes within a minute and offer up to eight hours of redness reduction," Joseph Papa, chairman and CEO of Bausch + Lomb parent company Valeant, said. "Lumify is unlike other redness relievers on the market and will provide consumers a new welcomed alternative."
Eye redness is a common, non-specific issue that affects millions of people. Other redness relievers are commonly associated with the potential side effects of rebound redness and loss of efficacy over time. Lumify works by selectively targeting redness and thereby reducing the potential for these side effects.
In clinical trials, Lumify eye drops demonstrated 95% improvement at one minute with significant results lasting up to eight hours. A recent in-home-use-study with more than 300 participants also resulted in a 95% satisfaction rating for the product.
"Lumify eye drops deliver a safe and effective redness relieving OTC option that my patients have been asking for," Paul Karpecki, director of Corneal Services at Kentucky Eye Institute, said. "I am excited to introduce these new eye drops into my practice and offer my patients long-lasting symptom relief without the adverse effects commonly associated with other redness relievers."
Lumify is available for purchase at retailers nationwide, including Walgreens, CVS, Rite Aid, Walmart, Target and Amazon. The bottles, available in 2.5 mL and 7.5 mL sizes, have suggested retail prices of $14.99 and $25.99, respectively.
"With the availability of Lumify, consumers now have an innovative, over-the-counter treatment option that can help relieve red, irritated eyes within a minute and offer up to eight hours of redness reduction," Joseph Papa, chairman and CEO of Bausch + Lomb parent company Valeant, said. "Lumify is unlike other redness relievers on the market and will provide consumers a new welcomed alternative."
Eye redness is a common, non-specific issue that affects millions of people. Other redness relievers are commonly associated with the potential side effects of rebound redness and loss of efficacy over time. Lumify works by selectively targeting redness and thereby reducing the potential for these side effects.
In clinical trials, Lumify eye drops demonstrated 95% improvement at one minute with significant results lasting up to eight hours. A recent in-home-use-study with more than 300 participants also resulted in a 95% satisfaction rating for the product.
"Lumify eye drops deliver a safe and effective redness relieving OTC option that my patients have been asking for," Paul Karpecki, director of Corneal Services at Kentucky Eye Institute, said. "I am excited to introduce these new eye drops into my practice and offer my patients long-lasting symptom relief without the adverse effects commonly associated with other redness relievers."
Lumify is available for purchase at retailers nationwide, including Walgreens, CVS, Rite Aid, Walmart, Target and Amazon. The bottles, available in 2.5 mL and 7.5 mL sizes, have suggested retail prices of $14.99 and $25.99, respectively.